<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Post-traumatic headache
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Post-traumatic headache
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Post-traumatic headache
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Henrik Winther Schytz, MD, PhD, DMSCi
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerry W Swanson, MD, MHPE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard P Goddeau, Jr, DO, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1888226633">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Post-traumatic headache (PTH) is a frequent sequela of traumatic brain injury (TBI). It may also occur as a feature of the postconcussion syndrome symptom complex. After TBI, some patients have short-term acute PTH (&lt;3 months) while PTH is persistent (&gt;3 months duration) in others.
        </p>
        <p>
         This topic discusses the epidemiology, clinical features, treatment, and prognosis of PTH. Other clinical syndromes related to TBI are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4830.html" rel="external">
          "Postconcussion syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111925.html" rel="external">
          "Sequelae of mild traumatic brain injury"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3026809381">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PTH is common after traumatic brain injury (TBI) and is the most frequent symptom after mild traumatic brain injury (mTBI) [
         <a href="#rid1">
          1
         </a>
         ]. It is estimated that annually 69 million suffer from TBI worldwide, mostly attributable to mTBI [
         <a href="#rid2">
          2
         </a>
         ]. In a meta-analysis of observational studies that included more than 3100 patients with PTH after TBI, the overall estimated prevalence was 47 percent [
         <a href="#rid3">
          3
         </a>
         ]. Among patients with mTBI, PTH prevalence ranges from 37 to 69 percent in observational studies [
         <a href="#rid4">
          4-8
         </a>
         ], compared with 32 percent reported for patients with moderate to severe TBI from an earlier systemic review [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Some patients report short-term PTH symptoms, resolving within three months of TBI [
         <a href="#rid4">
          4,5
         </a>
         ]. Others report chronic PTH symptoms [
         <a href="#rid9">
          9
         </a>
         ]. In one cohort of 1594 patients with mTBI who presented to an emergency department and underwent neuroimaging, acute PTH was reported in 60 percent [
         <a href="#rid8">
          8
         </a>
         ]. Lower rates of chronic PTH were observed at 3, 6, and 12 months, respectively (52 versus 38 versus 29 percent). Other studies have shown that up to 58 percent have PTH at 12 months [
         <a href="#rid4">
          4,10
         </a>
         ]. One study from Norway showed that 0.21 percent of patients with chronic headache had persistent PTH [
         <a href="#rid11">
          11
         </a>
         ], while the lifetime prevalence of PTH was 4.7 percent in males and 2.4 percent in females in a Danish population-based study [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         The incidence of PTH is primarily based on data from patients seeking immediate medical help at emergency clinics or when admitted to a trauma center. PTH among patients seeking help several days after the trauma, typically via general practitioners, is not well known. Additionally, PTH may be misclassified as migraine or another primary headache syndrome, especially in those with a preexisting history of headaches.
        </p>
        <p>
         The incidence of persistent PTH is inversely related to the degree of TBI, as PTH is found in 58 percent of patients with mTBI 12 months after the initial injury compared with 33 percent of patients with moderate to severe TBI [
         <a href="#rid13">
          13
         </a>
         ]. Athletes and military personnel with concussion are at risk for PTH, but the incidence in these groups may be underreported [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         There is little compelling evidence of risk factors for acute or persistent PTH [
         <a href="#rid15">
          15
         </a>
         ]. Several risk factors, however, have been identified in several observational series of patients with PTH [
         <a href="#rid4">
          4,5,8,16-18
         </a>
         ]. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age ≤60 years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Female sex
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mild (versus moderate or severe) TBI
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of prior TBI
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of prior headaches
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comorbid psychiatric conditions
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H999536148">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The underlying cause of PTH is not fully known, but mechanisms related to both migraine and traumatic brain injury (TBI) are implicated. These include impaired descending pain modulation, neurometabolic changes, neuroinflammation, cortical spreading depression, and release of the calcitonin gene-related peptide (CGRP) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The mechanisms that incite and sustain PTH may be more related to neuroinflammation and trigeminal system activation implicated in migraine and other primary headache disorders than those underlying TBI [
         <a href="#rid19">
          19
         </a>
         ]. TBI may cause both immediate effects of brain contusion, cerebral blood vessel damage, and axonal shearing and a secondary cascade of metabolic and cellular excitotoxic and inflammatory changes that can promote development of PTH [
         <a href="#rid20">
          20
         </a>
         ]. The precise relationship between these TBI mechanisms and PTH is not well understood.
        </p>
        <p>
         The similarities between PTH and migraine are supported by the observation that patients with PTH but no prior history of migraine have been shown to be hypersensitive to CGRP [
         <a href="#rid21">
          21
         </a>
         ]. CGRP is a neuropeptide that may mediate trigeminovascular pain transmission to trigger a migraine attack [
         <a href="#rid22">
          22
         </a>
         ]. CGRP antagonists are a class of medications for acute and preventive treatment of migraine. In study of patients with PTH, 28 percent had a 50 percent reduction in days with moderate or severe headache following an open-label treatment with
         <a class="drug drug_general" data-topicid="117927" href="/z/d/drug information/117927.html" rel="external">
          erenumab
         </a>
         , a CGRP receptor antagonist [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2447266665">
         <span class="h1">
          CLINICAL FEATURES AND DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H1635678964">
         <span class="h2">
          Headache features
         </span>
         <span class="headingEndMark">
          —
         </span>
         PTH symptoms are varied but often resemble the clinical features of primary headache syndromes and can be classified accordingly. Migraine-like and tension-type-like headaches are most common [
         <a href="#rid4">
          4,14,24-27
         </a>
         ]. In most series, tension-type-like headaches are most frequent (75 to 77 percent) [
         <a href="#rid25">
          25,26
         </a>
         ]; however, in others, migraine-type headaches predominate [
         <a href="#rid4">
          4,24
         </a>
         ]. Additionally, among United States soldiers with post-traumatic headaches mainly associated with blast trauma, most were migraine-like [
         <a href="#rid28">
          28
         </a>
         ]. Many patients (27 to 75 percent) have more than one type of headache [
         <a href="#rid26">
          26,29
         </a>
         ]. The headache burden may vary, but in one study of 100 patients with PTH, the mean frequency was 25 days each month [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         In rare cases, PTH symptoms may be consistent with other primary headaches. These include the trigeminal autonomic cephalgias (such as cluster headache [
         <a href="#rid30">
          30
         </a>
         ], short-lasting unilateral headache with cranial autonomic symptoms [SUNA] [
         <a href="#rid31">
          31
         </a>
         ], and paroxysmal hemicrania [PH] [
         <a href="#rid32">
          32
         </a>
         ]) as well as hemicrania continua [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Eliciting whether the headache pattern is migraine-like, tension-type-like, or resembling other headache disorders may help guide symptomatic therapy. (See
         <a class="local">
          'Treatment'
         </a>
         below.)
        </p>
        <p>
         In one study, acute PTH was described most often as having a bilateral localization (56 percent), a moderate or severe intensity (59 percent), and a pressing quality (69 percent) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Multiple triggers and aggravating factors of PTH have been reported. In one study, patients with persistent PTH with migraine-like symptoms reported bright lights lead to aggravation of headache, while those with tension-type-like headache symptoms reported stress and nervousness as headache-aggravating factors [
         <a href="#rid35">
          35
         </a>
         ]. By comparison, another study found that patients with migraine-like headache symptoms reported stress (73 percent), lack of sleep (69 percent), and bright lights (60 percent) as headache-aggravating factors [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2223547871">
         <span class="h2">
          Associated postconcussive symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PTH may also have other symptoms of post-concussion syndrome. These may include fatigue, dizziness, sleep difficulties, concentration impairment, and seizures. Depression, anxiety, and insomnia frequently occur after traumatic brain injury (TBI) and PTH [
         <a href="#rid36">
          36,37
         </a>
         ]. In addition, post-traumatic stress disorder may be present in more than 10 percent of patients after TBI [
         <a href="#rid38">
          38
         </a>
         ]. Post-concussive syndrome and other sequelae of TBI are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4830.html" rel="external">
          "Postconcussion syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/111925.html" rel="external">
          "Sequelae of mild traumatic brain injury"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1201822930">
         <span class="h2">
          Clinical diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         PTH is a clinical diagnosis made in a symptomatic patient who has sustained a TBI and meets diagnostic criteria. PTH is classified according to the International Classification of Headache Disorders (ICHD-3) as being acute or persistent and attributed to either mild TBI (mTBI) or moderate to severe TBI [
         <a href="#rid39">
          39
         </a>
         ]. The key criteria are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of head trauma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Onset of headache within seven days of trauma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache syndrome not better accounted for by another headache diagnosis
        </p>
        <p>
        </p>
        <p>
         The seven-day interval is somewhat arbitrary but may be useful to help exclude patients with isolated acute headaches who do not subsequently develop PTH. In some series, the onset of PTH after mild TBI has been reported to occur most commonly within 24 hours [
         <a href="#rid40">
          40
         </a>
         ], but other series reported delayed onset by several weeks after mild TBI in some patients [
         <a href="#rid4">
          4
         </a>
         ]. For patients with severe TBI, the seven-day interval may be delayed from the time of the TBI to the time when they regain consciousness and wean from medications that may interfere with the ability to sense or report headache symptoms.
        </p>
        <p>
         Acute PTH may last up to three months; if longer, symptoms are termed chronic or persistent PTH [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         There are no imaging or laboratory test findings to identify patients with or without PTH following TBI. Imaging studies or laboratory testing has been used in research settings. Clinical imaging techniques only need to be performed to rule out intracranial hemorrhages, such as parenchymal bleeding, epidural or subdural hemorrhages, and skull fracture. (See
         <a class="local">
          'Testing for alternative causes of headache'
         </a>
         below.)
        </p>
        <p>
         Several imaging and laboratory findings associated with PTH have been found in research settings. Magnetic resonance imaging (MRI) has shown that PTH is associated with abnormalities in brain structure and function [
         <a href="#rid41">
          41
         </a>
         ]. Compared with healthy controls, patients with persistent PTH show reduced cortical thickness in frontal regions and parietal regions compared with controls [
         <a href="#rid42">
          42
         </a>
         ]. Additionally, those with persistent PTH also showed differences in brain volume, surface area, fiber tract integrity, and functional connectivity compared with patients with migraine [
         <a href="#rid43">
          43-45
         </a>
         ]. In another study, patients with an elevated S100 calcium-binding protein B drawn six hours after TBI were likelier to have persistent PTH symptoms at six months than those without [
         <a href="#rid46">
          46
         </a>
         ]. Calcitonin gene-related peptide (CGRP) levels were modestly lower in patients with persistent PTH compared with age- and gender-matched controls [
         <a href="#rid47">
          47
         </a>
         ]. Oxylipins measured within three days of TBI were inversely associated with headache severity three months after the TBI [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
         Additional criteria may be applied to subcategorize patients with PTH according to severity of TBI. All of the following features are absent in PTH attributed to mTBI; if any are present, PTH is attributed to moderate or severe TBI [
         <a href="#rid39">
          39
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of consciousness for &gt;30 minutes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glasgow coma scale (GCS) score &lt;13  (
         <a class="graphic graphic_table graphicRef81854" href="/z/d/graphic/81854.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Post-traumatic amnesia or altered level of awareness for more than 24 hours
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Imaging evidence of a TBI (eg, skull fracture, intracranial hemorrhage, or brain contusion)
        </p>
        <p>
        </p>
        <p>
         In addition, PTH attributed to mTBI requires the headache is also associated any of the following symptoms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient confusion, disorientation, or impaired consciousness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of memory for events immediately before or after the head injury
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two or more symptoms of mTBI: nausea, vomiting, visual disturbances, dizziness or vertigo, gait imbalance, or impaired memory or concentration
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2349441506">
         <span class="h2">
          Testing for alternative causes of headache
         </span>
         <span class="headingEndMark">
          —
         </span>
         PTH is diagnosed clinically. History and examination may be helpful to identify patients with atypical symptoms or neurologic deficits suggestive of alternative diagnoses who warrant diagnostic testing. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuroimaging
         </strong>
         – Many patients with PTH will have had diagnostic neuroimaging with head computed tomography (CT) or magnetic resonance imaging (MRI) during the acute evaluation of the TBI. In other patients and patients whose symptoms or examination has worsened since acute imaging, we prefer brain MRI with gadolinium contrast if feasible. Additionally, CT or MR angiography of the head and neck are performed when carotid or vertebral artery dissection are suspected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other testing
         </strong>
         – Other diagnostic testing such as electroencephalogram (EEG) or lumbar puncture is reserved for patients with atypical symptoms or abnormal exam findings suggestive of alternate diagnoses.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4004144288">
         <span class="h2">
          Differential diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several other headache syndromes may occur after TBI. The specific headache symptoms and associated neurologic findings may help to discriminate from PTH.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intracranial hypotension (IH)
         </strong>
         – Headache may develop due to IH, which could be due to a dural tear. Symptoms favoring IH include onset of headache when sitting upright and resolution after lying horizontally [
         <a href="#rid49">
          49
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3359.html" rel="external">
          "Spontaneous intracranial hypotension: Pathophysiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subdural hematoma (SDH)
         </strong>
         – Persistent headache following a head trauma could be due to acute or chronic SDH. Patients may or may not have associated focal neurologic deficits. SDH is more common in the older adult population [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1105.html" rel="external">
          "Subdural hematoma in adults: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Occipital neuralgia
         </strong>
         – Injury to the head may also lead to traumatic neuralgias such as occipital neuralgia in which there is a usual one-sided paroxysmal, shooting, or stabbing pain in the posterior part of the head. This neuralgia is located in the distributions of the greater, lesser, and/or third occipital nerve and can be accompanied by tenderness and/or diminished sensation or dysesthesia in the affected area [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3330.html" rel="external">
          "Occipital neuralgia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trigeminal neuropathy
         </strong>
         – TBI could also lead to trigeminal neuropathy, with either positive (hyperalgesia, allodynia) or negative (hypoesthesia, hypoalgesia) signs of nerve dysfunction [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3355.html" rel="external">
          "Overview of craniofacial pain", section on 'Painful trigeminal neuropathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cervical artery dissection
         </strong>
         – Carotid or vertebral artery dissection can lead to headache, most often accompanied by ipsilateral neck and head or periorbital pain. Neurologic deficits associated with carotid artery dissection may include Horner's syndrome (ipsilateral ptosis, miosis, anhidrosis). Carotid or vertebral artery dissection may also cause acute ischemic stroke. (See
         <a class="medical medical_review" href="/z/d/html/14082.html" rel="external">
          "Cerebral and cervical artery dissection: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Temporomandibular joint (TMJ) disorders
         </strong>
         – TMJ may occur after TBI involving facial structures. Patients may report jaw pain and/or hemicranial headaches. (See
         <a class="medical medical_review" href="/z/d/html/5629.html" rel="external">
          "Temporomandibular disorders in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Premorbid headache syndromes
         </strong>
         – When a preexisting primary headache increases twofold or greater in frequency and/or severity in close temporal relation to a traumatic event, both the primary and the secondary headache diagnoses should be given [
         <a href="#rid39">
          39
         </a>
         ]. As an example, patients with migraine whose symptoms worsen twofold within seven days after TBI would be classified as having migraine and (migraine-like) PTH. (See
         <a class="medical medical_review" href="/z/d/html/3348.html" rel="external">
          "Pathophysiology, clinical manifestations, and diagnosis of migraine in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3357.html" rel="external">
          "Tension-type headache in adults: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication overuse headache (MOH)
         </strong>
         – Patients with a preexisting headache disorder who regularly take medications for symptomatic management of a headache occurring more than 15 days per month for at least 3 months may have MOH. Patients who meet diagnostic criteria for PTH and MOH are given both diagnoses. (See
         <a class="medical medical_review" href="/z/d/html/3340.html" rel="external">
          "Medication overuse headache: Etiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2939856432">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite being one of the most frequent secondary headache syndromes, there are no evidence-based treatment strategies for PTH. Treatment should not only focus on ameliorating headache symptoms but also other related symptoms if present, including those from postconcussion syndrome, which most frequently accompanies PTH. (See
         <a class="local">
          'Associated postconcussive symptoms'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4830.html" rel="external">
          "Postconcussion syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17740734">
         <span class="h2">
          Treatment approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with PTH, we start medications typically used to treat other primary headache syndromes. (See
         <a class="local">
          'Initial medication options'
         </a>
         below.)
        </p>
        <p>
         A systematic review of both acute and preventive pharmacologic treatment of PTH was limited to studies using an open-label design, those with investigator-subject interaction, and those with a high placebo response [
         <a href="#rid52">
          52
         </a>
         ]. In the absence of evidence-based options, we suggest that treatment should be tailored to the headache pattern that the specific PTH resembles [
         <a href="#rid14">
          14
         </a>
         ]. Thus, PTH treatment may follow the recommendations of migraine or tension-type headache. (See
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">
          "Preventive treatment of episodic migraine in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3358.html" rel="external">
          "Tension-type headache in adults: Acute treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3360.html" rel="external">
          "Tension-type headache in adults: Preventive treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4282962234">
         <span class="h2">
          Initial medication options
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although many patients with PTH may be treated according to the pattern of their headaches, we tailor our initial medication selection to patient comorbidities and medication risk-benefit profiles.
        </p>
        <p class="headingAnchor" id="H1640755364">
         <span class="h3">
          Acute treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with acute PTH or those with persistent PTH with infrequent attacks, acute treatment may manage symptoms and limit exposure to adverse drug effects.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment options
         </strong>
         – We typically start with a simple analgesic medication like
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         at 400 to 800 mg up to three times daily. As an alternative,
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         (paracetamol) at 500 to 1000 mg up to three times daily may be used. Analgesics to treat headaches are discussed in further detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults", section on 'Simple analgesics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3358.html" rel="external">
          "Tension-type headache in adults: Acute treatment", section on 'Simple analgesics for most patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients unresponsive to simple analgesics for acute therapy, we typically use a combination analgesic medication also containing
         <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">
          caffeine
         </a>
         before starting preventive therapy. (See
         <a class="medical medical_review" href="/z/d/html/3358.html" rel="external">
          "Tension-type headache in adults: Acute treatment", section on 'Combination analgesics with caffeine'
         </a>
         and
         <a class="local">
          'Preventive treatments'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with acute PTH and frequent attacks inadequately responsive to acute treatments and for patients with persistent PTH (&gt;3-month duration), we start a preventive medication. (See
         <a class="local">
          'Preventive treatments'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with nausea
         </strong>
         – Nausea accompanying the headache can be treated with antiemetics (eg,
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          metoclopramide
         </a>
         or
         <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">
          prochlorperazine
         </a>
         ). The role of antiemetics to treat headaches is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults", section on 'Antiemetics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative options
         </strong>
         – For other patients with migraine-like headache symptoms who do not respond to simple analgesics or analgesic medications combined with
         <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">
          caffeine
         </a>
         , alternative acute treatment options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Triptans
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Triptans combined with nonsteroidal anti-inflammatory drugs (NSAIDs)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Calcitonin gene-related peptide (CGRP) ligand-receptor antagonists
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dihydroergotamine-ergotamine alone or with
         <a class="drug drug_general" data-topicid="9213" href="/z/d/drug information/9213.html" rel="external">
          caffeine
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These approaches are discussed in further detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults", section on 'Triptans'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults", section on 'Triptans with NSAIDs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults", section on 'CGRP antagonists'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">
          "Acute treatment of migraine in adults", section on 'Ergots'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3584629267">
         <span class="h3">
          Preventive treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with persistent PTH and those with acute PTH and frequent attacks inadequately responsive to acute treatments, we start a preventive medication. The threshold to start a preventive medication is guided by the severity of symptoms and patient preference but may include those who have headache duration longer than 12 hours or have at least four monthly headache days.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with PTH where migraine-type headaches predominate, we prefer an antihypertensive medication such as
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         or
         <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">
          candesartan
         </a>
         . For those unresponsive to or unable to tolerate an antihypertensive or in patients with comorbid depression or neuropathic pain, we use
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         . Other medications used to prevent migraine are reasonable alternatives. (See
         <a class="medical medical_review" href="/z/d/html/3345.html" rel="external">
          "Preventive treatment of episodic migraine in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          Metoprolol
         </a>
         is started at 50 mg daily and after one week may be increased to 100 mg. After one to two months, the dose may be increased by 50 mg weekly, if tolerated, up to 200 mg daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">
          Candesartan
         </a>
         is started at 8 mg daily and after one week may be increased to 16 mg. The dose may be increased by 8 mg weekly, if tolerated, up to 32 mg. We measure serum electrolytes and supine blood pressure to evaluate for hyperkalemia, deterioration of renal function, or hypotension before treatment and when increasing the daily dosage of candesartan.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          Amitriptyline
         </a>
         can be started at 10 mg at bedtime and increased by 10 mg weekly, if tolerated, up to 100 mg at bedtime. We obtain an electrocardiogram to evaluate for arrhythmias before treatment and when the dose exceeds 40 mg daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with PTH where tension-type headaches predominate, we prefer
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         . Other medications used to prevent tension-type headaches are reasonable alternatives. (See
         <a class="medical medical_review" href="/z/d/html/3360.html" rel="external">
          "Tension-type headache in adults: Preventive treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          Amitriptyline
         </a>
         dosing is the same as for those with migraine-type headaches, discussed immediately above.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          Mirtazapine
         </a>
         is started at 15 mg at bedtime. The dose can be increased to 30 mg after one week. We obtain an electrocardiogram to evaluate for arrhythmias before treatment and when increasing the daily dosage.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          Venlafaxine
         </a>
         is started at 75 mg at bedtime. The dose can be increased to 150 mg after one week. We obtain an electrocardiogram to evaluate for arrhythmias before treatment and when increasing the daily dosage.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For the rare patient with clinical features of PTH that are neither migraine-type nor tension-type in character, we use the same preventive medication and dosing regimens as for patients with the primary headache syndromes to which the headaches resemble.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with PTH and medication overuse headache, we discontinue the overused medication and start a preventive medication. (See
         <a class="medical medical_review" href="/z/d/html/3341.html" rel="external">
          "Medication overuse headache: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         However, it is important to be aware that this approach lacks evidence and the efficacy has, when reported, been poor [
         <a href="#rid53">
          53
         </a>
         ]. In addition, side effects to pharmacologic treatment may conflict with PTH comorbidities such as post-traumatic stress disorder, depression, and anxiety. Additionally, medication overuse headache is also very frequent among patients with PTH. As an example, among 167 participants with mild traumatic brain injury (mTBI), who prospectively reported new or worse headache at 3, 6, or 12 months, more than 70 percent used over-the-counter medication to treat headache [
         <a href="#rid54">
          54
         </a>
         ]. Furthermore, in a study of 77 adolescents with concussion and persistent PTH, 70 percent met criteria for probable medication-overuse headache [
         <a href="#rid55">
          55
         </a>
         ]. After discontinuing analgesics, 69 percent reported resolution of headaches or improvement to pre-concussion headache patterns [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2667500556">
         <span class="h2">
          Alternative therapeutic options
         </span>
         <span class="headingEndMark">
          —
         </span>
         As there is no high-quality evidence to support a pharmacologic agent to treat PTH, some patients may prefer nonpharmacologic treatment options. Such options are included in a guideline for concussion/mTBI and persistent symptoms from the Ontario Neurotrauma Foundation [
         <a href="#rid56">
          56
         </a>
         ]. Nonpharmacologic options include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Physical or manual therapies [
         <a href="#rid57">
          57
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exercise [
         <a href="#rid58">
          58
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Avoidance of headache triggers [
         <a href="#rid59">
          59
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Progressive muscle relaxation [
         <a href="#rid60">
          60
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sleep hygiene education [
         <a href="#rid61">
          61
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietary and environment modifications [
         <a href="#rid59">
          59
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cognitive behavioral therapy [
         <a href="#rid57">
          57,62
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H905266761">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with acute PTH do not develop persistent PTH, as headaches may resolve spontaneously or with treatment within three months of the traumatic brain injury (TBI). In one study of 397 children with TBI, recovery was slower when PTH had migraine-like features [
         <a href="#rid63">
          63
         </a>
         ]. However, the natural history of PTH is not well described, and prognostic data on patients with PTH are sparse.
        </p>
        <p>
         Some insight into the prognosis of PTH may be found from patients with PTH as a component of neuropsychiatric symptoms after TBI. Most patients with postconcussion syndrome typically recover within 3 to 12 months [
         <a href="#rid64">
          64
         </a>
         ]. However, for others, PTH may be chronic. In one study of 110 patients with mild TBI (mTBI), 76 percent reported headaches at one month and 58 percent reported persisting PTH at a mean follow up of 98 days [
         <a href="#rid65">
          65
         </a>
         ]. In another study, only 30 percent of 116 patients with PTH reported headache resolution by 24 months after TBI [
         <a href="#rid66">
          66
         </a>
         ]. The persistence of PTH for some patients after TBI may reflect secondary chronic post-inflammatory and metabolic changes related to migrainous pathophysiology, but further study is required to clarify these issues [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3690163391">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116408.html" rel="external">
          "Society guideline links: Increased intracranial pressure and moderate-to-severe traumatic brain injury"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H416984156">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17132.html" rel="external">
          "Patient education: Postconcussion syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1184867156">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and clinical setting
         </strong>
         – Post-traumatic headache (PTH) is a frequent sequela of traumatic brain injury (TBI). It may also occur as a feature of the postconcussion syndrome symptom complex. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – PTH symptoms are varied but can be classified similarly to primary headache syndromes to which the clinical features resemble. Migraine-like and tension-type-like headaches are most common. (See
         <a class="local">
          'Headache features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – PTH is a clinical diagnosis made in a symptomatic patient with an onset of headache within seven days after a TBI when the headache syndrome is not better accounted for by another headache diagnosis. Acute PTH may last up to three months; if longer, symptoms are termed chronic or persistent PTH. (See
         <a class="local">
          'Clinical diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment approach
         </strong>
         – For patients with PTH, we start medications typically used to treat other primary headache syndromes and tailor our initial medication selection to patient comorbidities and medication risk-benefit profiles. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute treatment
         </strong>
         – For patients with acute PTH or those with persistent PTH with infrequent attacks, acute treatment may manage symptoms and limit exposure to adverse effects of medications. For most patients, we suggest initial treatment with a simple analgesic medication like
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         or
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         (paracetamol) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients with symptoms unresponsive to simple analgesics, we use combination analgesics or abortive therapies commonly used for migraine headaches including triptans, calcitonin gene-related peptide (CGRP) antagonists, or dihydroergotamine-ergotamine. (See
         <a class="local">
          'Acute treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preventive treatment
         </strong>
         – For patients with persistent PTH and those with acute PTH and frequent attacks inadequately responsive to acute treatments, we start a preventive medication.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with PTH where migraine-type headaches predominate, we suggest an antihypertensive medication such as
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         or
         <a class="drug drug_general" data-topicid="8670" href="/z/d/drug information/8670.html" rel="external">
          candesartan
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For those unresponsive to or unable to tolerate an antihypertensive or in patients with comorbid depression or neuropathic pain, we suggest
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Other medications used to prevent migraine are reasonable alternatives.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with PTH where tension-type headaches predominate, we suggest
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Other medications used to prevent tension-type headaches are reasonable alternatives.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – Some patients with acute PTH do not develop persistent PTH, as headaches may resolve spontaneously or with treatment. However, for others, PTH may become chronic. The natural history of PTH is not well described, and prognostic data on patients with PTH are sparse. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Nampiaparampil DE. Prevalence of chronic pain after traumatic brain injury: a systematic review. JAMA 2008; 300:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maas AIR, Menon DK, Adelson PD, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol 2017; 16:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrero Babiloni A, Bouferguene Y, Exposto FG, et al. The prevalence of persistent post-traumatic headache in adult civilian traumatic brain injury: a systematic review and meta-analysis on the past 14 years. Pain 2023; 164:2627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lucas S, Hoffman JM, Bell KR, Dikmen S. A prospective study of prevalence and characterization of headache following mild traumatic brain injury. Cephalalgia 2014; 34:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yilmaz T, Roks G, de Koning M, et al. Risk factors and outcomes associated with post-traumatic headache after mild traumatic brain injury. Emerg Med J 2017; 34:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cnossen MC, van der Naalt J, Spikman JM, et al. Prediction of Persistent Post-Concussion Symptoms after Mild Traumatic Brain Injury. J Neurotrauma 2018; 35:2691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theeler BJ, Flynn FG, Erickson JC. Headaches after concussion in US soldiers returning from Iraq or Afghanistan. Headache 2010; 50:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashina H, Dodick DW, Barber J, et al. Prevalence of and Risk Factors for Post-traumatic Headache in Civilian Patients After Mild Traumatic Brain Injury: A TRACK-TBI Study. Mayo Clin Proc 2023; 98:1515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voormolen DC, Haagsma JA, Polinder S, et al. Post-Concussion Symptoms in Complicated vs. Uncomplicated Mild Traumatic Brain Injury Patients at Three and Six Months Post-Injury: Results from the CENTER-TBI Study. J Clin Med 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu H, Pi H, Ma L, et al. Incidence of Headache After Traumatic Brain Injury in China: A Large Prospective Study. World Neurosurg 2016; 88:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aaseth K, Grande RB, Kvaerner KJ, et al. Prevalence of secondary chronic headaches in a population-based sample of 30-44-year-old persons. The Akershus study of chronic headache. Cephalalgia 2008; 28:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen BK, Olesen J. Symptomatic and nonsymptomatic headaches in a general population. Neurology 1992; 42:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjeldgaard D, Forchhammer HB, Teasdale TW, Jensen RH. Cognitive behavioural treatment for the chronic post-traumatic headache patient: a randomized controlled trial. J Headache Pain 2014; 15:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashina H, Eigenbrodt AK, Seifert T, et al. Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment. Lancet Neurol 2021; 20:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen AM, Ashina H, Iljazi A, et al. Risk Factors for the Development of Post-Traumatic Headache Attributed to Traumatic Brain Injury: A Systematic Review. Headache 2020; 60:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman JM, Lucas S, Dikmen S, et al. Natural history of headache after traumatic brain injury. J Neurotrauma 2011; 28:1719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stacey A, Lucas S, Dikmen S, et al. Natural History of Headache Five Years after Traumatic Brain Injury. J Neurotrauma 2017; 34:1558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawyer K, Bell KR, Ehde DM, et al. Longitudinal Study of Headache Trajectories in the Year After Mild Traumatic Brain Injury: Relation to Posttraumatic Stress Disorder Symptoms. Arch Phys Med Rehabil 2015; 96:2000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashina H, Porreca F, Anderson T, et al. Post-traumatic headache: epidemiology and pathophysiological insights. Nat Rev Neurol 2019; 15:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ladak AA, Enam SA, Ibrahim MT. A Review of the Molecular Mechanisms of Traumatic Brain Injury. World Neurosurg 2019; 131:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashina H, Iljazi A, Al-Khazali HM, et al. Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache. Ann Neurol 2020; 88:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 2019; 394:1765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashina H, Iljazi A, Al-Khazali HM, et al. Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. J Headache Pain 2020; 21:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashina H, Iljazi A, Al-Khazali HM, et al. Persistent post-traumatic headache attributed to mild traumatic brain injury: Deep phenotyping and treatment patterns. Cephalalgia 2020; 40:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas DC. Chronic post-traumatic headaches classified and compared with natural headaches. Cephalalgia 1996; 16:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baandrup L, Jensen R. Chronic post-traumatic headache--a clinical analysis in relation to the International Headache Classification 2nd Edition. Cephalalgia 2005; 25:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuczynski A, Crawford S, Bodell L, et al. Characteristics of post-traumatic headaches in children following mild traumatic brain injury and their response to treatment: a prospective cohort. Dev Med Child Neurol 2013; 55:636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vargas BB. Posttraumatic headache in combat soldiers and civilians: what factors influence the expression of tension-type versus migraine headache? Curr Pain Headache Rep 2009; 13:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couch JR, Bearss C. Chronic daily headache in the posttrauma syndrome: relation to extent of head injury. Headache 2001; 41:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Formisano R, Angelini A, De Vuono G, et al. Cluster-like headache and head injury: case report. Ital J Neurol Sci 1990; 11:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob S, Saha A, Rajabally Y. Post-traumatic short-lasting unilateral headache with cranial autonomic symptoms (SUNA). Cephalalgia 2008; 28:991.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matharu MJ, Goadsby PJ. Post-traumatic chronic paroxysmal hemicrania (CPH) with aura. Neurology 2001; 56:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lay CL, Newman LC. Posttraumatic hemicrania continua. Headache 1999; 39:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieba-Samal D, Platzer P, Seidel S, et al. Characteristics of acute posttraumatic headache following mild head injury. Cephalalgia 2011; 31:1618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy D, Gruener H, Riabinin M, et al. Different clinical phenotypes of persistent post-traumatic headache exhibit distinct sensory profiles. Cephalalgia 2020; 40:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SK, Chong CD, Dumkrieger G, et al. Clinical correlates of insomnia in patients with persistent post-traumatic headache compared with migraine. J Headache Pain 2020; 21:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martins HAL, Martins BBM, Ribas VR, et al. Life quality, depression and anxiety symptoms in chronic post-traumatic headache after mild brain injury. Dement Neuropsychol 2012; 6:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iljazi A, Ashina H, Al-Khazali HM, et al. Post-Traumatic Stress Disorder After Traumatic Brain Injury-A Systematic Review and Meta-Analysis. Neurol Sci 2020; 41:2737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langer LK, Bayley MT, Lawrence DW, et al. Revisiting the ICHD-3 criteria for headache attributed to mild traumatic injury to the head: Insights from the Toronto Concussion Study Analysis of Acute Headaches Following Concussion. Cephalalgia 2022; 42:1172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwedt TJ. Structural and Functional Brain Alterations in Post-traumatic Headache Attributed to Mild Traumatic Brain Injury: A Narrative Review. Front Neurol 2019; 10:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong CD, Berisha V, Chiang CC, et al. Less Cortical Thickness in Patients With Persistent Post-Traumatic Headache Compared With Healthy Controls: An MRI Study. Headache 2018; 58:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dumkrieger G, Chong CD, Ross K, et al. Static and dynamic functional connectivity differences between migraine and persistent post-traumatic headache: A resting-state magnetic resonance imaging study. Cephalalgia 2019; 39:1366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwedt TJ, Chong CD, Peplinski J, et al. Persistent post-traumatic headache vs. migraine: an MRI study demonstrating differences in brain structure. J Headache Pain 2017; 18:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong CD, Peplinski J, Berisha V, et al. Differences in fibertract profiles between patients with migraine and those with persistent post-traumatic headache. Cephalalgia 2019; 39:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Kruijk JR, Leffers P, Menheere PP, et al. Prediction of post-traumatic complaints after mild traumatic brain injury: early symptoms and biochemical markers. J Neurol Neurosurg Psychiatry 2002; 73:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ashina H, Al-Khazali HM, Iljazi A, et al. Low plasma levels of calcitonin gene-related peptide in persistent post-traumatic headache attributed to mild traumatic brain injury. Cephalalgia 2020; 40:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Domenichiello AF, Jensen JR, Zamora D, et al. Identifying oxidized lipid mediators as prognostic biomarkers of chronic posttraumatic headache. Pain 2020; 161:2775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman DI. Headaches Due to Low and High Intracranial Pressure. Continuum (Minneap Minn) 2018; 24:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen JC, Levy ML. Causes, epidemiology, and risk factors of chronic subdural hematoma. Neurosurg Clin N Am 2000; 11:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen EL, Ashina H, Iljazi A, et al. Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review. J Headache Pain 2019; 20:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeeberg P, Olesen J, Jensen R. Efficacy of multidisciplinary treatment in a tertiary referral headache centre. Cephalalgia 2005; 25:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiTommaso C, Hoffman JM, Lucas S, et al. Medication usage patterns for headache treatment after mild traumatic brain injury. Headache 2014; 54:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heyer GL, Idris SA. Does analgesic overuse contribute to chronic post-traumatic headaches in adolescent concussion patients? Pediatr Neurol 2014; 50:464.
          </a>
         </li>
         <li class="breakAll">
          Ontario Neurotrauma Foundation. Guideline For Concussion/Mild Traumatic Brain Injury &amp; Prolonged Symptoms, 3rd Edition, for Adults over 18 years of age. https://braininjuryguidelines.org/concussion/ (Accessed on September 28, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Argyriou AA, Mitsikostas DD, Mantovani E, et al. An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management. Expert Rev Neurother 2021; 21:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Register-Mihalik JK, Vander Vegt CB, Cools M, Carnerio K. Factors Associated with Sport-Related Post-concussion Headache and Opportunities for Treatment. Curr Pain Headache Rep 2018; 22:75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverberg ND, Martin P, Panenka WJ. Headache Trigger Sensitivity and Avoidance after Mild Traumatic Brain Injury. J Neurotrauma 2019; 36:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usmani S, Balcer L, Galetta S, Minen M. Feasibility of Smartphone-Delivered Progressive Muscle Relaxation in Persistent Post-Traumatic Headache Patients. J Neurotrauma 2021; 38:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruff RL, Ruff SS, Wang XF. Improving sleep: initial headache treatment in OIF/OEF veterans with blast-induced mild traumatic brain injury. J Rehabil Res Dev 2009; 46:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraser F, Matsuzawa Y, Lee YSC, Minen M. Behavioral Treatments for Post-Traumatic Headache. Curr Pain Headache Rep 2017; 21:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein SK, Brown CB, Ostrowski-Delahanty S, et al. Identifying Migraine Phenotype Post Traumatic Headache (MPTH) to Guide Overall Recovery From Traumatic Brain Injury. J Child Neurol 2022; :8830738221100327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll LJ, Cassidy JD, Peloso PM, et al. Prognosis for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med 2004; :84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashluba S, Paniak C, Blake T, et al. A longitudinal, controlled study of patient complaints following treated mild traumatic brain injury. Arch Clin Neuropsychol 2004; 19:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane R, Davies P. Post traumatic headache (PTH) in a cohort of UK compensation claimants. Cephalalgia 2019; 39:641.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 128470 Version 9.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18698069" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prevalence of chronic pain after traumatic brain injury: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29122524" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37390366" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The prevalence of persistent post-traumatic headache in adult civilian traumatic brain injury: a systematic review and meta-analysis on the past 14 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23921798" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A prospective study of prevalence and characterization of headache following mild traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28689194" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Risk factors and outcomes associated with post-traumatic headache after mild traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29690799" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prediction of Persistent Post-Concussion Symptoms after Mild Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20553333" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Headaches after concussion in US soldiers returning from Iraq or Afghanistan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37480909" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prevalence of and Risk Factors for Post-traumatic Headache in Civilian Patients After Mild Traumatic Brain Injury: A TRACK-TBI Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31717436" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Post-Concussion Symptoms in Complicated vs. Uncomplicated Mild Traumatic Brain Injury Patients at Three and Six Months Post-Injury: Results from the CENTER-TBI Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26746335" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Incidence of Headache After Traumatic Brain Injury in China: A Large Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18498398" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prevalence of secondary chronic headaches in a population-based sample of 30-44-year-old persons. The Akershus study of chronic headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1603351" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Symptomatic and nonsymptomatic headaches in a general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25441170" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cognitive behavioural treatment for the chronic post-traumatic headache patient: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34022171" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32320055" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Risk Factors for the Development of Post-Traumatic Headache Attributed to Traumatic Brain Injury: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21732765" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Natural history of headache after traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27927072" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Natural History of Headache Five Years after Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26220236" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Longitudinal Study of Headache Trajectories in the Year After Mild Traumatic Brain Injury: Relation to Posttraumatic Stress Disorder Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31527806" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Post-traumatic headache: epidemiology and pathophysiological insights.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31301445" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A Review of the Molecular Mechanisms of Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32959458" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31668411" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Targeting calcitonin gene-related peptide: a new era in migraine therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32493206" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32102546" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Persistent post-traumatic headache attributed to mild traumatic brain injury: Deep phenotyping and treatment patterns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8933993" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Chronic post-traumatic headaches classified and compared with natural headaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15658950" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Chronic post-traumatic headache--a clinical analysis in relation to the International Headache Classification 2nd Edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23560811" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Characteristics of post-traumatic headaches in children following mild traumatic brain injury and their response to treatment: a prospective cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19889289" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Posttraumatic headache in combat soldiers and civilians: what factors influence the expression of tension-type versus migraine headache?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11437891" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Chronic daily headache in the posttrauma syndrome: relation to extent of head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2387704" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cluster-like headache and head injury: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18513261" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Post-traumatic short-lasting unilateral headache with cranial autonomic symptoms (SUNA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11160973" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Post-traumatic chronic paroxysmal hemicrania (CPH) with aura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613225" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Posttraumatic hemicrania continua.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22116940" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Characteristics of acute posttraumatic headache following mild head injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31847569" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Different clinical phenotypes of persistent post-traumatic headache exhibit distinct sensory profiles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32295535" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical correlates of insomnia in patients with persistent post-traumatic headache compared with migraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29213773" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Life quality, depression and anxiety symptoms in chronic post-traumatic headache after mild brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32415640" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Post-Traumatic Stress Disorder After Traumatic Brain Injury-A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35546269" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Revisiting the ICHD-3 criteria for headache attributed to mild traumatic injury to the head: Insights from the Toronto Concussion Study Analysis of Acute Headaches Following Concussion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31258507" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Structural and Functional Brain Alterations in Post-traumatic Headache Attributed to Mild Traumatic Brain Injury: A Narrative Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29139130" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Less Cortical Thickness in Patients With Persistent Post-Traumatic Headache Compared With Healthy Controls: An MRI Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31042064" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Static and dynamic functional connectivity differences between migraine and persistent post-traumatic headache: A resting-state magnetic resonance imaging study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28831776" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Persistent post-traumatic headache vs. migraine: an MRI study demonstrating differences in brain structure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30913910" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Differences in fibertract profiles between patients with migraine and those with persistent post-traumatic headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12438478" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prediction of post-traumatic complaints after mild traumatic brain injury: early symptoms and biochemical markers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32689824" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Low plasma levels of calcitonin gene-related peptide in persistent post-traumatic headache attributed to mild traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32694380" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Identifying oxidized lipid mediators as prognostic biomarkers of chronic posttraumatic headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30074550" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Headaches Due to Low and High Intracranial Pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10918008" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Causes, epidemiology, and risk factors of chronic subdural hematoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23771276" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The International Classification of Headache Disorders, 3rd edition (beta version).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31638888" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16305604" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy of multidisciplinary treatment in a tertiary referral headache centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24741687" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Medication usage patterns for headache treatment after mild traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24656666" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Does analgesic overuse contribute to chronic post-traumatic headaches in adolescent concussion patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24656666" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Does analgesic overuse contribute to chronic post-traumatic headaches in adolescent concussion patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33682560" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30203116" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Factors Associated with Sport-Related Post-concussion Headache and Opportunities for Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30489228" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Headache Trigger Sensitivity and Avoidance after Mild Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32484070" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Feasibility of Smartphone-Delivered Progressive Muscle Relaxation in Persistent Post-Traumatic Headache Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20437313" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Improving sleep: initial headache treatment in OIF/OEF veterans with blast-induced mild traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28283812" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Behavioral Treatments for Post-Traumatic Headache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35656769" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Identifying Migraine Phenotype Post Traumatic Headache (MPTH) to Guide Overall Recovery From Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15083873" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Prognosis for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15288333" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : A longitudinal, controlled study of patient complaints following treated mild traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30409039" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Post traumatic headache (PTH) in a cohort of UK compensation claimants.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
